Human Follistatin Quantikine ELISA Kit | R&D Systems DFN00 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

R&D Systems

product type :

ELISA/assay

product name :

Human Follistatin Quantikine ELISA Kit

catalog :

DFN00

quantity :

1 Kit

price :

655 USD

citations: 36

Reference
Nawrocka Millward S, Biegus J, Fudim M, Guzik M, Iwanek G, Ponikowski P, et al. The role of urine chloride in acute heart failure. Sci Rep. 2024;14:14100 pubmed publisher
Baccouche B, Lietuvninkas L, Kazlauskas A. Activin A Limits VEGF-Induced Permeability via VE-PTP. Int J Mol Sci. 2023;24: pubmed publisher
Tao R, St xf6 hr O, Wang C, Qiu W, COPPS K, White M. Hepatic follistatin increases basal metabolic rate and attenuates diet-induced obesity during hepatic insulin resistance. Mol Metab. 2023;71:101703 pubmed publisher
Richter M, Svane M, Kristiansen V, Holst J, Madsbad S, Bojsen M xf8 ller K. Postprandial secretion of follistatin after gastric bypass surgery and sleeve gastrectomy. Peptides. 2023;163:170978 pubmed publisher
Baumgartner M, Lischka J, Schanzer A, de Gier C, Walleczek N, Greber Platzer S, et al. Plasma Myostatin Increases with Age in Male Youth and Negatively Correlates with Vitamin D in Severe Pediatric Obesity. Nutrients. 2022;14: pubmed publisher
Perry C, Van Guilder G, Butterick T. Decreased myostatin in response to a controlled DASH diet is associated with improved body composition and cardiometabolic biomarkers in older adults: results from a controlled-feeding diet intervention study. BMC Nutr. 2022;8:24 pubmed publisher
Amasene M, Cadenas Sanchez C, Echeverria I, Sanz B, Alonso C, Tobalina I, et al. Effects of Resistance Training Intervention along with Leucine-Enriched Whey Protein Supplementation on Sarcopenia and Frailty in Post-Hospitalized Older Adults: Preliminary Findings of a Randomized Controlled Trial. J Clin Med. 2021;11: pubmed publisher
Nawrocka Millward S, Biegus J, Hurkacz M, Guzik M, Rosiek Biegus M, Jankowska E, et al. Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure. Biomolecules. 2021;11: pubmed publisher
Wu C, Borné Y, Gao R, López Rodríguez M, Roell W, Wilson J, et al. Elevated circulating follistatin associates with an increased risk of type 2 diabetes. Nat Commun. 2021;12:6486 pubmed publisher
Du Y, Xu C, Shi H, Jiang X, Tang W, Wu X, et al. Serum concentrations of oxytocin, DHEA and follistatin are associated with osteoporosis or sarcopenia in community-dwelling postmenopausal women. BMC Geriatr. 2021;21:542 pubmed publisher
He Z, Tian Y, Valenzuela P, Huang C, Zhao J, Hong P, et al. Myokine/Adipokine Response to "Aerobic" Exercise: Is It Just a Matter of Exercise Load?. Front Physiol. 2019;10:691 pubmed publisher
Sarcar S, Tulalamba W, Rincon M, Tipanee J, Pham H, Evens H, et al. Next-generation muscle-directed gene therapy by in silico vector design. Nat Commun. 2019;10:492 pubmed publisher
He Z, Tian Y, Valenzuela P, Huang C, Zhao J, Hong P, et al. Myokine Response to High-Intensity Interval vs. Resistance Exercise: An Individual Approach. Front Physiol. 2018;9:1735 pubmed publisher
Fife E, Kostka J, Kroc Ł, Guligowska A, Pigłowska M, Sołtysik B, et al. Relationship of muscle function to circulating myostatin, follistatin and GDF11 in older women and men. BMC Geriatr. 2018;18:200 pubmed publisher
Tao R, Wang C, Stöhr O, Qiu W, Hu Y, Miao J, et al. Inactivating hepatic follistatin alleviates hyperglycemia. Nat Med. 2018;24:1058-1069 pubmed publisher
Ma J, Pichavant C, du Bois H, Bhakta M, Calos M. DNA-Mediated Gene Therapy in a Mouse Model of Limb Girdle Muscular Dystrophy 2B. Mol Ther Methods Clin Dev. 2017;7:123-131 pubmed publisher
Elliott B, Herbert P, Sculthorpe N, Grace F, Stratton D, Hayes L. Lifelong exercise, but not short-term high-intensity interval training, increases GDF11, a marker of successful aging: a preliminary investigation. Physiol Rep. 2017;5: pubmed publisher
Ikeda K, Ito A, Imada R, Sato M, Kawabe Y, Kamihira M. In vitro drug testing based on contractile activity of C2C12 cells in an epigenetic drug model. Sci Rep. 2017;7:44570 pubmed publisher
Papaporfyriou A, Bakakos P, Kostikas K, Papatheodorou G, Hillas G, Trigidou R, et al. Activin A and follistatin in patients with asthma. Does severity make the difference?. Respirology. 2017;22:473-479 pubmed publisher
Wilson C, Ottewell P, Coleman R, Holen I. The differential anti-tumour effects of zoledronic acid in breast cancer - evidence for a role of the activin signaling pathway. BMC Cancer. 2015;15:55 pubmed publisher
Näf S, Escote X, Ballesteros M, Yañez R, Simón Muela I, Gil P, et al. Serum activin A and follistatin levels in gestational diabetes and the association of the Activin A-Follistatin system with anthropometric parameters in offspring. PLoS ONE. 2014;9:e92175 pubmed publisher
Yaden B, Croy J, Wang Y, Wilson J, Datta Mannan A, Shetler P, et al. Follistatin: a novel therapeutic for the improvement of muscle regeneration. J Pharmacol Exp Ther. 2014;349:355-71 pubmed publisher
Leddy H, McNulty A, Lee S, Rothfusz N, Gloss B, Kirby M, et al. Follistatin in chondrocytes: the link between TRPV4 channelopathies and skeletal malformations. FASEB J. 2014;28:2525-37 pubmed publisher
Ferguson B, Gao X, Zelazowski M, Lee J, Jeter C, Abba M, et al. The cancer gene WWOX behaves as an inhibitor of SMAD3 transcriptional activity via direct binding. BMC Cancer. 2013;13:593 pubmed publisher
Chen Y, Wu Y, Yang W, Wang S, Lee C, Chou N, et al. Relationship between bone mineral density and serum osteoprotegerin in patients with chronic heart failure. PLoS ONE. 2012;7:e44242 pubmed publisher
Karve T, Preet A, Sneed R, Salamanca C, Li X, Xu J, et al. BRCA1 regulates follistatin function in ovarian cancer and human ovarian surface epithelial cells. PLoS ONE. 2012;7:e37697 pubmed publisher
Jeppesen J, Nielsen M, Kristensen S, Yding Andersen C. Concentration of activin A and follistatin in follicular fluid from human small antral follicles associated to gene expression of the corresponding granulosa cells. Mol Cell Endocrinol. 2012;356:48-54 pubmed publisher
Hansen J, Brandt C, Nielsen A, Hojman P, Whitham M, Febbraio M, et al. Exercise induces a marked increase in plasma follistatin: evidence that follistatin is a contraction-induced hepatokine. Endocrinology. 2011;152:164-71 pubmed publisher
Sun Y, Ge Y, Drnevich J, Zhao Y, Band M, Chen J. Mammalian target of rapamycin regulates miRNA-1 and follistatin in skeletal myogenesis. J Cell Biol. 2010;189:1157-69 pubmed publisher
Foley J, Bercury S, Finn P, Cheng S, Scheule R, Ziegler R. Evaluation of systemic follistatin as an adjuvant to stimulate muscle repair and improve motor function in Pompe mice. Mol Ther. 2010;18:1584-91 pubmed publisher
Weigert J, Neumeier M, Wanninger J, Schober F, Sporrer D, Weber M, et al. Adiponectin upregulates monocytic activin A but systemic levels are not altered in obesity or type 2 diabetes. Cytokine. 2009;45:86-91 pubmed publisher
Eijken M, Swagemakers S, Koedam M, Steenbergen C, Derkx P, Uitterlinden A, et al. The activin A-follistatin system: potent regulator of human extracellular matrix mineralization. FASEB J. 2007;21:2949-60 pubmed
Miller T, Kim S, Yamanaka K, Hester M, Umapathi P, Arnson H, et al. Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2006;103:19546-51 pubmed
Tardif G, Hum D, Pelletier J, Boileau C, Ranger P, Martel Pelletier J. Differential gene expression and regulation of the bone morphogenetic protein antagonists follistatin and gremlin in normal and osteoarthritic human chondrocytes and synovial fibroblasts. Arthritis Rheum. 2004;50:2521-30 pubmed
Abe Y, Abe T, Aida Y, Hara Y, Maeda K. Follistatin restricts bone morphogenetic protein (BMP)-2 action on the differentiation of osteoblasts in fetal rat mandibular cells. J Bone Miner Res. 2004;19:1302-7 pubmed
Leal A, Takabe K, Wang L, Donaldson C, Macconell L, Bilezikjian L, et al. Effect of adenovirus-mediated overexpression of follistatin and extracellular domain of activin receptor type II on gonadotropin secretion in vitro and in vivo. Endocrinology. 2002;143:964-9 pubmed

product information

master code :

DFN00

SKU :

DFN00

product name :

Human Follistatin Quantikine ELISA Kit

unit size :

1 Kit

description :

The Human Follistatin Quantikine ELISA Kit from R&D Systems is a Solid Phase Sandwich ELISA that quantifies human Follistatin in cell culture supernates (10 ul), serum (100 ul), edta plasma (100 ul), follicular fluid (10 ul).

target :

Follistatin

category :

ELISAs

species :

Human

specificity :

Natural and recombinant human Follistatin

gene symbol :

FST

kit type :

Solid Phase Sandwich ELISA

assay length :

5.5 hours

elisaSampleTypes :

Cell Culture Supernates (10 uL), Serum (100 uL), EDTA Plasma (100 uL), Follicular Fluid (10 uL)

elisaSensitivity :

83 pg/mL

elisaRange :

250.00 - 16000 pg/mL

top caption :

Human Follistatin ELISA Cell Culture Supernate Standard Curve

applications :

ELISA

USD :

655 USD

product details :

The Quantikine Human Follistatin Immunoassay is a 5.5 hour solid-phase ELISA designed to measure human Follistatin (FS288, FS300, and FS315) in follicular fluid, cell culture supernates, serum, and plasma. It contains Sf 21-expressed recombinant human Follistatin and antibodies raised against the recombinant factor. It has been shown to accurately quantitate recombinant human Follistatin. Results obtained using natural Follistatin showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for natural Follistatin.

alt names :

follistatin, follistatin isoform FST317, FS, FSActivin-binding protein, FST

storage :

Store the unopened product at 2 - 8 ░C. Do not use past expiration date.